Robert Chess an Insider in Nektar Therapeutics (NKTR) Unloaded 25,000 Shares of the Company; 5 Bullish Analysts Covering Horizon North Logistics Inc. (TSE:HNL)

Horizon North Logistics Inc. (TSE:HNL) Logo

Horizon North Logistics Inc. (TSE:HNL) Ratings Coverage

Among 5 analysts covering Horizon North Logistics Inc. (TSE:HNL), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Horizon North Logistics Inc. had 20 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was maintained by TD Securities with “Action List Buy” on Friday, July 29. Raymond James upgraded it to “Outperform” rating and $2 target in Thursday, April 13 report. Raymond James maintained Horizon North Logistics Inc. (TSE:HNL) on Thursday, March 2 with “Market Perform” rating. On Wednesday, November 2 the stock rating was maintained by TD Securities with “Action List Buy”. The stock of Horizon North Logistics Inc. (TSE:HNL) earned “Outperform” rating by Scotia Capital on Friday, July 22. The rating was downgraded by Raymond James to “Market Perform” on Monday, August 15. See Horizon North Logistics Inc. (TSE:HNL) latest ratings:

11/12/2017 Broker: National Bank Canada Rating: Outperform Old Target: $2.40 New Target: $1.90 Target Down

The stock increased 1.71% or $0.04 during the last trading session, reaching $2.38. About 74,293 shares traded. Horizon North Logistics Inc. (TSE:HNL) has 0.00% since May 5, 2017 and is . It has underperformed by 11.55% the S&P500.

Horizon North Logistics Inc., a remote resource development service company, provides workforce accommodation solutions, camp management and catering services, and road and access matting solutions. The company has market cap of $348.43 million. It operates through two divisions, Camps & Catering, and Rentals & Logistics. It currently has negative earnings. The Camps & Catering segment offers workforce accommodation, camp rental, and catering services; and makes and sells camps, as well as provides related transportation and installation services.

More recent Nektar Therapeutics (NASDAQ:NKTR) news were published by: Seekingalpha.com which released: “Nektar Therapeutics: What The REVEAL Study Entails” on April 13, 2018. Also Nasdaq.com published the news titled: “Can These Top-Performing Biotech Stocks Keep Climbing?” on April 30, 2018. Streetinsider.com‘s news article titled: “Nektar Therapeutics (NKTR) Says Pact With Takeda to Evaluate Combination of NKTR-214, a CD122-biased Agonist ..” with publication date: April 24, 2018 was also an interesting one.

Since December 13, 2017, it had 0 insider purchases, and 18 insider sales for $68.39 million activity. Hora Maninder had sold 502 shares worth $53,046 on Tuesday, April 10. The insider CHESS ROBERT sold 25,000 shares worth $2.30M. Nicholson John sold $21.85 million worth of stock. The insider Labrucherie Gil M sold 3,477 shares worth $288,382. The insider ROBIN HOWARD W sold $6.32M. The insider Thomsen Jillian B. sold $1.41 million. Another trade for 30,000 shares valued at $2.77M was made by GREER R SCOTT on Friday, April 6.

The well-informed person Robert Chess who is director of Nektar Therapeutics unloaded some 25,000 shares of the California-based Nektar Therapeutics valued at near $2,070,050 US Dollars based on an average weighted cost of $82.8 of a share. He also unloaded 25,000 shares with a total value $2,303,600 USD in the last month. This large trade will probably draw attention, as Robert Chess right now owns 0.16% of the market capitalization of Nektar Therapeutics.

Nektar Therapeutics develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the United States. The company has market cap of $13.22 billion. The Company’s product pipeline includes drug candidates in therapeutic areas comprising cancer, auto-immune disease, and chronic pain. It currently has negative earnings. The firm offers MOVANTIK, an oral peripherally-acting opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain; MOVENTIG for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives; and ADYNOVATE for use in treating Hemophilia A.

Among 11 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 11 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Nektar Therapeutics has $125 highest and $16 lowest target. $78.10’s average target is 1.17% above currents $77.2 stock price. Nektar Therapeutics had 27 analyst reports since August 6, 2015 according to SRatingsIntel. On Thursday, March 29 the stock rating was maintained by Mizuho with “Buy”. The firm earned “Buy” rating on Monday, June 5 by Aegis Capital. The stock has “Buy” rating by Roth Capital on Wednesday, August 30. The rating was reinitiated by H.C. Wainwright on Monday, April 2 with “Buy”. Roth Capital maintained Nektar Therapeutics (NASDAQ:NKTR) on Monday, November 13 with “Buy” rating. The stock of Nektar Therapeutics (NASDAQ:NKTR) earned “Buy” rating by Jefferies on Wednesday, October 18. Jefferies maintained the stock with “Buy” rating in Wednesday, November 8 report. The stock of Nektar Therapeutics (NASDAQ:NKTR) earned “Buy” rating by Canaccord Genuity on Wednesday, January 10. The firm has “Hold” rating by TheStreet given on Wednesday, August 26. The company was maintained on Wednesday, August 9 by Roth Capital.

The stock decreased 6.71% or $5.55 during the last trading session, reaching $77.2. About 3.64M shares traded or 20.64% up from the average. Nektar Therapeutics (NASDAQ:NKTR) has risen 347.01% since May 5, 2017 and is uptrending. It has outperformed by 335.46% the S&P500.

Nektar Therapeutics (NASDAQ:NKTR) Institutional Positions Chart